Overview


According to FutureWise analysis the market for clinical trial supplies in 2023 is US$ 3.95 billion, and is expected to reach US$ 8.3 billion by 2031 at a CAGR of 9.70%.

A safe clinical trial necessitates a well-managed supply chain for the research medications, in accordance with numerous regional and global legislation and infrastructures. Overproduction, inventory expiration, and oversupply can all be avoided with proper clinical trial supplies management. Clinical trial supplies market are becoming more important as the expenses of drug development rise. Furthermore, as a result of the installation of stricter handling standards for a range of biopharmaceutical products entering clinical trials, the clinical trial supplies strategy must be updated on a regular basis. This necessitates incorporating multiple third-party vendors throughout the clinical development process.Clinical trial supplies cover a wide range of tools and equipment used in scientific tests, investigations, and clinical research. The most widely utilised clinical trial supplies include infusion pumps, nebulizers, and syringe needles. They're mostly utilised in medical trials for identifying, preventing, and treating various illnesses, evaluating the efficacy of a treatment technique, and diagnosing infectious and metabolic problems. They're also used for a variety of procedures in the pulmonary, oncological, cardiovascular, and neurological fields. Globalization, an increase in the number of clinical trials, and an increase in the number of biologics and biosimilar pharmaceuticals in clinical trials are all contributing to the growth.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Clinical Trial Supplies Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Clinical Trial Supplies Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Catalent, Inc.
  • Pra Health Sciences
  • Biocair
  • Almac Group
  • Thermo Fisher Scientific
  • Piramal Pharma Solutions
  • Udg Healthcare
  • Eurofins
  • Marken
  • Infosys
  • Pci Pharma Services
  • Pra Health Sciences
  • Liveo Research
  • Capsuge
  • Klifo
  • Clinigen
  • Siro Clinpharm
  • Ancillare
  • N-side
  • Adallen Pharm
  • Rubicon Research
  • Durbin
  • Recipharm
  • Seveillar Clinical Supplies Services
  • Myonex

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Services

  • Storage and Retention
  • Packaging, Labeling, and Blinding
  • Manufacturing
  • Comparator Sourcing
  • Logistics and Distribution
  • Other Services

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Type

  • Small-Molecule Drugs
  • Biologic Drugs
  • Medical Devices

By Therapeutic Area

  • Oncology
  • Cns and Mental Disorders
  • Cardiovascular Diseases
  • Digestive Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Blood Disorders
  • Immunology
  • Other Therapeutic Areas

By End-User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Medical Device Companies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Clinical Trial Supplies Market By Services, By Phase, By Type, By Therapeutic Area, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Clinical Trial Supplies Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Clinical Trial Supplies Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Clinical Trial Supplies Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Clinical Trial Supplies Market, By Services Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Storage and Retention
        2. Packaging, Labeling, and Blinding
        3. Manufacturing
        4. Comparator Sourcing
        5. Logistics and Distribution
        6. Other Services

  • 8.   Clinical Trial Supplies Market, By Phase Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV

  • 9.   Clinical Trial Supplies Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Small-Molecule Drugs
        2. Biologic Drugs
        3. Medical Devices

  • 10.   Clinical Trial Supplies Market, By Therapeutic Areas Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology
        2. Cns and Mental Disorders
        3. Cardiovascular Diseases
        4. Digestive Disorders
        5. Infectious Diseases
        6. Metabolic Disorders
        7. Blood Disorders
        8. Immunology
        9. Other Therapeutic Areas

  • 11.   Clinical Trial Supplies Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceutical and Biotechnology Companies
        2. Contract Research Organizations
        3. Medical Device Companies

  • 12.   North America Clinical Trial Supplies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Clinical Trial Supplies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Clinical Trial Supplies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Clinical Trial Supplies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Clinical Trial Supplies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Catalent, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pra Health Sciences
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Biocair
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Almac Group
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Thermo Fisher Scientific
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Piramal Pharma Solutions
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Udg Healthcare
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Eurofins
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Marken
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Infosys
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Pci Pharma Services
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Pra Health Sciences
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Liveo Research
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Capsugel
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Siro Clinpharm
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Klifo
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Clinigen
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Ancillare
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. N-side
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Adallen Pharma
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         .20.5. Strategic Overview
        21. Rubicon Research
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Durbin
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. Recipharm
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. Seveillar Clinical Supplies Services
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. Myonex
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients